Neurobiological Technologies Is Focused On The Phase 3 Trials For Their Viprinex™ Compound For Acute Ischemic Stroke |
|
|
Neurobiological Technologies, Inc. (NTII-NASDAQ) |
|
|
“When you get into the product portfolio itself, stroke is a very important indication and it is one of the most underserved indication in the world.” - Paul E. Freiman (NTII) (Interview published June 27, 2008) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|
Become a member and access our interview with: Paul E. Freiman, CEO (NTII)
|
|
